Lexology January 10, 2024
Morrison & Foerster LLP

The year 2023 was a busy one for regulatory, compliance, and enforcement developments in the healthcare and life sciences industries, and 2024 promises to be even busier. We tapped MoFo’s Life Sciences + Healthcare Compliance and Enforcement Group for a 2024 preview, and here is what our team of former government officials from the U.S. Department of Justice (DOJ), Food and Drug Administration (FDA), and Department of Health and Human Services (HHS), former in-house compliance counsel, privacy lawyers, and veteran defense attorneys have offered up.

Stay tuned for a series of podcasts and webcasts from our team throughout 2024, where they will dive deep into each of the following predictions. To receive regular thought leadership and relevant event invitations, subscribe...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Regulations
BCBS Massachusetts weight loss drug spend jumps 250%: 5 notes
GLP-1 reduced heart failure risk by 46%: 8 study takeaways
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
NVIDIA BioNeMo Framework Accelerates AI Drug Discovery
Drugmakers' 340B rebate fight, explained

Share This Article